EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Oral Delivery of Gemcitabine-Loaded Glycocholic Acid-Modified Micelles for Cancer Therapy

Wenqing Zang, Duo Gao, Miaorong Yu, Manmei Long, Zhuan Zhang, Tianhai Ji iD

ACS Nano · 26.09.2023 · 17 (18) · 18074-18088

DOI: 10.1021/acsnano.3c04793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 17.09.2023. Verfasst von Wenqing Zang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China. Hauptthemen laut MEDLINE: Gemcitabine, Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Association for Science and Technology, School of Medicine, Shanghai Jiao Tong University, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical utility of gemcitabine, an antimetabolite antineoplastic agent applied in various chemotherapy treatments, is limited due to the required intravenous injection. Although chemical structure modifications of gemcitabine result in enhanced oral bioavailability, these modifications compromise complex synthetic routes and cause unexpected side effects. In this study, gemcitabine-loaded glycocholic acid-modified micelles (Gem-PPG) were prepared for enhanced oral chemotherapy. The in vitro transport pathway experiments revealed that intact Gem-PPG were transported across the intestinal epithelial monolayer via an apical sodium-dependent bile acid transporter (ASBT)-mediated pathway. In mice, the pharmacokinetic analyses demonstrated that the oral bioavailability of Gem-PPG approached 81%, compared to less than 20% for unmodified micelles. In addition, the antitumor activity of oral Gem-PPG (30 mg/kg, BIW) was superior to that of free drug injection (60 mg/kg, BIW) in the xenograft model. Moreover, the assessments of hematology, blood chemistry, and histology all indicated the hypotoxicity profile of the drug-loaded micelles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabineNeoplasmsHumansAnimalsMiceMicellesAdministration, OralGlycocholic Acid

Stichwörter der Autor:innen

chemotherapygemcitabineglycocholic acidmicellesoral delivery

Substanzen

GemcitabineMicellesGlycocholic Acid

Autor:innen und Institutionen

  • Department of Pathology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.

ORCID-Profile: Tianhai Ji

Förderung

  • China Association for Science and Technology
  • School of Medicine, Shanghai Jiao Tong University
  • China Postdoctoral Science Foundation
  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Zang, W., Gao, D., Yu, M., Long, M., Zhang, Z., & Ji, T. (2023). Oral Delivery of Gemcitabine-Loaded Glycocholic Acid-Modified Micelles for Cancer Therapy. ACS Nano, 17(18), 18074-18088. https://doi.org/10.1021/acsnano.3c04793

Vancouver

Zang W, Gao D, Yu M, Long M, Zhang Z, Ji T. Oral Delivery of Gemcitabine-Loaded Glycocholic Acid-Modified Micelles for Cancer Therapy. ACS Nano. 2023;17(18):18074-18088. doi:10.1021/acsnano.3c04793

BibTeX
@article{Zang2023,
  author = {Zang, Wenqing and Gao, Duo and Yu, Miaorong and Long, Manmei and Zhang, Zhuan and Ji, Tianhai},
  title = {Oral Delivery of Gemcitabine-Loaded Glycocholic Acid-Modified Micelles for Cancer Therapy},
  journal = {ACS Nano},
  year = {2023},
  volume = {17},
  number = {18},
  pages = {18074--18088},
  doi = {10.1021/acsnano.3c04793}
}
Kostenlos starten →